None listed
Conditions
Interventions
Dietary Supplement : This is an 8-week, randomized, double-blind, placebo-controlled, two-arm parallel-group clinical trial in healthy adults. Following screening and eligibility confirmation, partici
Sponsors
JBKLAB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult men or women aged =30 and =59 years Body mass index (BMI) =23 and <30 kg/m² Able to provide written informed consent and voluntarily agree to participate in the study
Exclusion criteria
Exclusion criteria: 1. Inability to perform treadmill exercise 2. Engagement in regular moderate-intensity exercise within 3 months (12 weeks) prior to the screening visit (e.g., brisk walking at least 30 minutes per day, 3 days per week) 3. Current smokers (individuals who have quit smoking for at least 1 year prior to the screening visit are eligible) 4. Excessive alcohol consumption (=420 g/week; approximately 7 bottles of soju per week or 1 bottle per day), alcohol dependence, or drug abuse 5. Presence or history within 2 years prior to the screening visit of the following conditions: - Hypertension, diabetes mellitus, atherosclerosis, chronic inflammatory diseases (e.g., rheumatoid arthritis), cardiovascular disease, renal disease, hepatic disease, thyroid disorders, malignancy, or psychiatric disorders - Any other condition deemed inappropriate for participation by the investigator 6. Continuous use within 1 month (4 weeks) prior to the screening visit of medications that may affect antioxidant status (e.g., lipid-lowering agents, anti-inflammatory drugs, antihypertensive agents, antibiotics, aspirin, glucose-lowering agents, or anticoagulants) 7. Use within 1 month (4 weeks) prior to the screening visit of functional foods or herbal medicines that may affect antioxidant status (e.g., red ginseng, chlorella, green tea extract, spirulina, propolis extract, coenzyme Q10, squalene, or tomato extract) 8. Serum creatinine level >2.0 mg/dL at the screening visit 9. AST or ALT levels =3 times the upper limit of normal at the screening visit 10. Gastrointestinal diseases that may affect absorption of the study product (e.g., Crohn’s disease, chronic dyspepsia, irritable bowel syndrome), or history of surgery within 6 months (24 weeks) prior to the screening visit 11. Pregnant or breastfeeding, or planning pregnancy during the study period 12. Known hypersensitivity or allergy to any component of the study product 13. Participation in another clinical trial within 3 months (12 weeks) prior to the screening visit 14. Any other condition that the investigator deems unsuitable for study participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to Week 4 and Week 8 in MDA(Malondialdehyde) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to Week4 and Week 8 in GSH(Reduced Glutathione), GSSG(Oxidized Glutathione), GSSG/GSH ratio;Change from baseline to Week4 and Week 8 in SOD(Superoxide Dismutase) ;Change from baseline to Week4 and Week 8 in Catalase;Change from baseline to Week 8 in GPx(Glutathione peroxidase);Change from baseline to Week 8 in 8-OHdG | — |
Countries
Korea, Republic of
Contacts
Public ContactSeon Mi Shin
Semyung University Oriental Medicine Hospital
Outcome results
None listed